News Summary
NegativeMedline delivered double-digit revenue growth (11.6% in Q2 2026) but triggered a severe 14.8% stock decline due to profitability pressures and disappointing earnings execution, prompting multiple analyst price-target cuts and spurring a securities fraud investigation by plaintiffs' law firms. Insider selling via large secondary offerings ($2.7B in May 2026) combined with deteriorating net income and persistent input cost concerns signal fundamental challenges beneath the topline growth.
Red flags
- •Q2 2026 earnings triggered 14.8% stock drop despite 11.6% revenue growth — suggests major earnings miss or guidance disappointment
- •Net income declined 25.8% in Q1 2026 despite 10.7% revenue growth — persistent profitability deterioration
- •Active securities litigation investigation by Kaplan Fox & Kilsheimer LLP (filed Aug–Sept 2026) related to post-earnings stock collapse
- •Multiple analyst price-target cuts: Barclays cut to $45 from $50; Baird cut to $45 from $57, signaling loss of confidence
- •Significant insider selling: Abu Dhabi Investment Authority and sponsor affiliates sold ~159M shares (~$2.7B gross proceeds) in two secondary offerings (March and May 2026) — suggests limited confidence in near-term outlook
- •Input cost pressures highlighted repeatedly through mid-2026, with Barclays specifically citing this concern in May
Funds Reducing / Exiting (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | 4.8M | -6,592,741 | $191M | 1.4% | -58% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 2.6M | -4,638,500 | $104M | 3.3% | -64% | Existing |
| Maverick Capital | Lee Ainslie | 0 | −796K | — | 0.4% | -100% | EXITED |
| Point72 | Steve Cohen | 0 | −3.3M | — | 0.3% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 4 | 3.70 | -13.3% |
| Q1 2026 | LONG | 4 | 4.85 | -39.4% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| GIC Private Ltd | — | SELL | 100K | $35.80 | $3.58M | 2026-08-14 | ↗ |
| GIC Private Ltd | — | SELL | 1.5M | $35.80 | $53.70M | 2026-08-13 | ↗ |
| GIC Private Ltd | — | SELL | 590K | $35.58 | $21.00M | 2026-08-07 | ↗ |
| GIC Private Ltd | — | SELL | 272K | $35.33 | $9.61M | 2026-08-06 | ↗ |
| GIC Private Ltd | — | SELL | 1.7M | $35.46 | $60.67M | 2026-08-05 | ↗ |
| GIC Private Ltd | — | SELL | 266K | $36.48 | $9.69M | 2026-08-05 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Hellman & Friedman Capital Partners X (Parallel), L.P. | SC 13G/A | 61.1M | 6.4% | 2026-08-11 | ↗ |
| BX Mozart ML-2 Holdco L.P. | SC 13G/A | 89.5M | 10.2% | 2026-08-07 | ↗ |
| FMR LLC | SC 13G | 46.9M | 5.5% | 2026-08-06 | ↗ |
| Carlyle Group Inc. | SC 13G/A | 187.1M | 20.6% | 2026-05-15 | ↗ |
| Abu Dhabi Investment Authority | SC 13G/A | 41.4M | 4.9% | 2026-05-07 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | SC 13G/A | 74.5M | 7.9% | 2026-05-06 | ↗ |
| BX Mozart ML-2 Holdco L.P. | SC 13G/A | 109.3M | 12.9% | 2026-05-01 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.